Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration

• Register: ClinicalTrials.gov
• Last refreshed on: 19 April 2022
• Main ID: NCT01367444
• Date of registration: 03/06/2011
• Prospective Registration: Yes
• Primary sponsor: Sanofi
• Public title: Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration
• Scientific title: A Phase I/IIA Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients With Stargardt's Macular Degeneration
• Date of first enrolment: June 8, 2011
• Target sample size: 27
• Recruitment status: Terminated
• URL: https://clinicaltrials.gov/show/NCT01367444
• Study type: Interventional
• Study design: Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 1/Phase 2

Countries of recruitment

France, United States

Contacts

• Name: Jose-Alain Sahel, MD. Ph.D
• Affiliation: Hopital Nationale des Quinze-Vingt, Paris France

• Name: Paul Yang, MD
• Affiliation: Oregon Health & Science University, Portland, Oregon

Key inclusion & exclusion criteria

Inclusion Criteria:

- Signed and dated written informed consent obtained from the participant and/or the
participant's legally acceptable representative.

- Diagnosis of SMD, with at least one pathogenic mutant ABCA4 allele on each chromosome.

- Women of childbearing potential must had a negative pregnancy test at Day -1, and
agree to use an effective form of contraception for at least three months, or be
surgically sterile or postmenopausal, with the last menstrual period being over two
years prior to enrollment.

- Males must agree with their partner to use two forms of contraception for at least
three months following SAR422459 administration.

- Participants must agree to not donate blood, organs, tissues or cells for at least
three months following SAR422459 administration.

- Participants enrolled in France must be affiliated to or benefit from a social
security regimen.

Specific Inclusion Criteria Participant Group A:

- Participants (18 years or older) with advanced SMD.

- Visual acuity less than or equal to (<=) 20/200 in the worst eye.

- Severe cone-rod dysfunction with no detectable or severely abnormal full-field
electroretinogram responses.

Specific Inclusion Criteria Participant Group B:

- Participants (18 years or older) with SMD.

- Visual Acuity <=20/200 in the worst eye.

- Abnormal full-field electroretinogram responses.

Specific Inclusion Criteria Participant Group C:

- Participants (18 years or older) with SMD.

- Visual acuity <=20/100 in the worst eye.

- Abnormal full-field electroretinogram responses.

Specific Inclusion Criteria Participant Group D:

- Symptomatic participants (from 6 years to 26 years old) with early or childhood-onset
SMD (age at disease onset [less than] <18 years) with at least one pathogenic mutant
ABCA4 allele on each chromosome confirmed by direct sequencing and co-segregation
analysis within the participant's family.

- Visual acuity of greater than or equal to (>=) 20/200 in both eyes at the time of the
screening visit.

- Participants were anticipated to experience rapid deterioration in visual function
and/or retinal structure as determined by an annual progression rate in at least one
of the following parameters occurring in at least one eye (assessments recorded up to
2 years prior to the screening visit date might be considered to document evidence of
rapid deterioration):

- Loss of >=1 line of Snellen visual acuity (equivalent to 5 early treatment
diabetic retinopathy study [ETDRS] letters).

- Reduction in macular mean sensitivity of >=1.2 decibels (dB) as assessed by
microperimetry.

- Reduction in macular mean sensitivity of >=5 dB or reduction in hill of vision by
greater than (>)14 dB-sr as assessed by static perimetry.

- Enlargement in the area of macular retinal pigment epithelial (RPE) atrophy by
fundus autofluorescence at a rate of >=0.5 millimeter square(mm^2).

- Enlargement in the area of central macular retinal thinning/photoreceptor loss by
ocular coherence tomography at a rate of >=0.5 mm^2.

- All eligible participants must demonstrate an ability to understand, willingness to
cooperate and ability to reliably perform required study procedures as judged and
confirmed by the study investigator.

Specific inclusion criteria Participant Group E:

- Symptomatic participants (between 6 years and 17 years old) with early or
childhood-onset SMD with at least one pathogenic mutant ABCA4 allele on each
chromosome confirmed by direct sequencing and co-segregation analysis within the
participant's family.

- Visual acuity of >=20/100 in both eyes at the time of screening visit.

- Participants were anticipated to experience rapid deterioration in visual function
and/or retinal structure as determined by an annual progression rate in at least one
of the following parameters occurring in at least one eye (assessments recorded up to
2 years prior to the screening visit date were considered to document evidence of
rapid deterioration):

- Loss of >=1 line of Snellen visual acuity (equivalent to 5 ETDRS letters).

- Reduction in macular mean sensitivity of >=1.2 dB as assessed by microperimetry.

- Reduction in macular mean sensitivity of >=5 dB or reduction in hill of vision by
>14 dB-sr as assessed by static perimetry.

- Enlargement in the area of macular RPE atrophy by fundus autofluorescence at a
rate of >=0.5 mm^2.

- Enlargement in the area of central macular retinal thinning/photoreceptor loss by
ocular coherence tomography at a rate of >=0.5 mm^2.

- All eligible participants demonstrated an ability to understand, willingness to
cooperate and ability to reliably perform required study procedures as judged and
confirmed by the study investigator.

Exclusion Criteria:

- Pre-existing eye conditions that would preclude the planned surgery or interfere with
the interpretation of study outcome measures.

- Cataract surgery with intraocular lens implantation within 6 months of enrolment.

- Aphakia or prior vitrectomy in the study eye.

- Concomitant systemic diseases including those in which the disease itself, or the
treatment for the disease, can alter ocular function.

- Any intraocular surgery or laser in either eye planned within 6 months of Day 0.

- Any contraindication to pupil dilation in either eye.

- Any known allergy to any component of the delivery vehicle or diagnostic agents used
during the study, or medications planned for use in the perioperative period
particularly topical, injected or systemic corticosteroids.

- Any injectable intravitreal treatment to the treated eye or intravitreal device in the
treated eye within 6 months prior to screening.

- Any periocular injections of corticosteroids to the treated eye within 4 months prior
to screening.

- Laboratory test abnormalities or abnormalities in electrocardiogram, chest X-rays that
in the opinion of the Principal Investigator would make the participant unsuitable for
participation in the study.

- Significant intercurrent illness or infection during the 28 days prior to enrolment.

- Pre-menopausal or non-surgically sterile women who were unwilling to use an effective
form of contraception such as the contraceptive pill or intrauterine de


Age minimum: 6 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Stargardt's Disease

Intervention(s)

Drug: SAR422459

Primary Outcome(s)

Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) [Time Frame: From Baseline to Week 48]

Percentage of Participants With TEAEs by Severity [Time Frame: From Baseline to Week 48]

Secondary ID(s)

SG1/001/10

TDU13583

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Results

• Results available: Yes
• Date Posted: 05/06/2020
• URL: https://clinicaltrials.gov/ct2/show/results/NCT01367444